Wish the speed and success of all of BD1s test could have been a...

Wish the speed and success of all of BD1s test could have been a bit faster.

"Curative therapy, including chest RT for Hodgkin lymphoma, is associated with a definitively increased risk of breast cancer, most often manifesting approximately 20 years after treatment. These breast cancers tend to be more aggressive, with greater frequency of hormone receptor negativity and potential HER2 positivity. Oncology (Williston Park). 30(12):1072–1073.When Hodgkin's disease, now referred to as Hodgkin lymphoma, was first described in 1853, it was a deadly disease. Patients usually died within months of diagnosis, and treatment was focused on improving patient comfort. In 1954, an era where only 5% of patients with Hodgkin lymphoma survived, Drs. Henry Kaplan and Edward Ginzton invented the first medical linear accelerator in the Western Hemisphere to deliver therapeutic radiotherapy (RT) with improved accuracy and potency, leading to curative outcomes in a group of patients with Hodgkin lymphoma.[1] Around this time, DeVita et al demonstrated the first curative combination chemotherapy in cancer, the MOPP (nitrogen mustard, vincristine, procarbazine, and prednisone) regimen for patients with Hodgkin lymphoma.[2] The concept of combined-modality treatment was advanced by Dr. Kaplan and Dr. Saul Rosenberg, who demonstrated that extended-field RT and combination chemotherapy could be curative for Hodgkin lymphoma patients.[3,4] Despite these advances, the late toxicities of chemotherapy and increased risk of secondary malignancies with RT have threatened the survival rates and quality of life of Hodgkin lymphoma patients. What is the cost of curing Hodgkin lymphoma, particularly in our young population?"https://www.cancernetwork.com/view/breast-cancer-after-hodgkin-lymphoma-price-success

A family member is a cancer survivor of 30 years. She beat the odds 30 years ago and did do 10 more than this 20 year estimated risk.